BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Al-Akash SI, Almond PS, Savell VH, Gharaybeh SI, Hogue C. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol. 2011;26:613-619. [PMID: 21125405 DOI: 10.1007/s00467-010-1708-6] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Blasco Pelicano M, Rodríguez de Córdoba S, Campistol Plana JM. Síndrome hemolítico urémico atípico. Medicina Clínica 2015;145:438-45. [DOI: 10.1016/j.medcli.2014.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Alasfar S, Alachkar N. Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature. Front Med (Lausanne) 2014;1:52. [PMID: 25593925 DOI: 10.3389/fmed.2014.00052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
3 Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Noël LH. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12:3337-3354. [PMID: 22958221 DOI: 10.1111/j.1600-6143.2012.04252.x] [Cited by in Crossref: 168] [Cited by in F6Publishing: 141] [Article Influence: 16.8] [Reference Citation Analysis]
4 Heinen S, Pluthero FG, van Eimeren VF, Quaggin SE, Licht C. Monitoring and modeling treatment of atypical hemolytic uremic syndrome. Mol Immunol 2013;54:84-8. [PMID: 23220071 DOI: 10.1016/j.molimm.2012.10.044] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
5 Bajracharya P, Jain A, Baracco R, Mattoo TK, Kapur G. Atypical hemolytic uremic syndrome: a clinical conundrum. Pediatr Nephrol 2016;31:1615-24. [PMID: 27139899 DOI: 10.1007/s00467-016-3369-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
6 Cochat P, Harambat J, Leclerc A. Recurrent Disease in Pediatric Renal Transplantation. Curr Pediatr Rep 2013;1:60-7. [DOI: 10.1007/s40124-012-0004-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Patschan D, Korsten P, Behlau A, Vasko R, Heeg M, Sweiss N, Müller GA, Koziolek M. Idiopathic combined, autoantibody-mediated ADAMTS-13/factor H deficiency in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in a 17-year-old woman: a case report. J Med Case Rep 2011;5:598. [PMID: 22206706 DOI: 10.1186/1752-1947-5-598] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
8 Kavanagh D, Goodship TH. Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations. Hematology Am Soc Hematol Educ Program. 2011;2011:15-20. [PMID: 22160007 DOI: 10.1182/asheducation-2011.1.15] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
9 Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 2016;89:701-11. [PMID: 26880462 DOI: 10.1016/j.kint.2015.11.026] [Cited by in Crossref: 141] [Cited by in F6Publishing: 119] [Article Influence: 23.5] [Reference Citation Analysis]
10 Greenbaum LA. Atypical Hemolytic Uremic Syndrome. Advances in Pediatrics 2014;61:335-56. [DOI: 10.1016/j.yapd.2014.04.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
11 Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, Cheung B, Machin SJ; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158:323-335. [PMID: 22624596 DOI: 10.1111/j.1365-2141.2012.09167.x] [Cited by in Crossref: 453] [Cited by in F6Publishing: 342] [Article Influence: 45.3] [Reference Citation Analysis]
12 Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643-657. [PMID: 23026949 DOI: 10.1038/nrneph.2012.214] [Cited by in Crossref: 349] [Cited by in F6Publishing: 291] [Article Influence: 34.9] [Reference Citation Analysis]
13 Tschumi S, Gugger M, Bucher BS, Riedl M, Simonetti GD. Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. Pediatr Nephrol 2011;26:2085-8. [DOI: 10.1007/s00467-011-1989-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
14 Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs. 2013;73:2053-2066. [PMID: 24249647 DOI: 10.1007/s40265-013-0147-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
15 Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol 2019;34:2261-77. [PMID: 30402748 DOI: 10.1007/s00467-018-4091-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
16 Noris M, Remuzzi G. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens. 2013;22:704-712. [PMID: 24076560 DOI: 10.1097/mnh.0b013e328365b3fe] [Cited by in Crossref: 40] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
17 Watanabe T. Renal complications of seasonal and pandemic influenza A virus infections. Eur J Pediatr 2013;172:15-22. [PMID: 23064728 DOI: 10.1007/s00431-012-1854-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
18 Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol. 2011;26:1325-1329. [PMID: 21556717 DOI: 10.1007/s00467-011-1879-9] [Cited by in Crossref: 79] [Cited by in F6Publishing: 69] [Article Influence: 7.2] [Reference Citation Analysis]
19 Loirat C, Saland J, Bitzan M. Management of hemolytic uremic syndrome. Presse Med. 2012;41:e115-e135. [PMID: 22284541 DOI: 10.1016/j.lpm.2011.11.013] [Cited by in Crossref: 69] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
20 Ge S, Hertel B, Emden SH, Beneke J, Menne J, Haller H, von Vietinghoff S. Microparticle generation and leucocyte death in Shiga toxin-mediated HUS. Nephrol Dial Transplant. 2012;27:2768-2775. [PMID: 22234918 DOI: 10.1093/ndt/gfr748] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
21 Carr R, Cataland SR. Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation. Ann Hematol 2013;92:845-6. [PMID: 23154867 DOI: 10.1007/s00277-012-1622-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
22 Schramm EC, Roumenina LT, Rybkine T, Chauvet S, Vieira-Martins P, Hue C, Maga T, Valoti E, Wilson V, Jokiranta S. Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood. 2015;125:2359-2369. [PMID: 25608561 DOI: 10.1182/blood-2014-10-609073] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 11.3] [Reference Citation Analysis]
23 Cho HJ, Kim JO, Huh JY, Park Y, Kim MG, Oh D. A case of atypical hemolytic uremic syndrome associated with the c.1273C>T mutation in the complement C3 gene. Blood Res 2016;51:210-3. [PMID: 27722136 DOI: 10.5045/br.2016.51.3.210] [Reference Citation Analysis]
24 Igarashi T, Ito S, Sako M, Saitoh A, Hataya H, Mizuguchi M, Morishima T, Ohnishi K, Kawamura N, Kitayama H. Guidelines for the management and investigation of hemolytic uremic syndrome. Clin Exp Nephrol. 2014;18:525-557. [PMID: 25099085 DOI: 10.1007/s10157-014-0995-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
25 Mizuno M, Ito Y, Morgan BP. Exploiting the nephrotoxic effects of venom from the sea anemone, Phyllodiscus semoni, to create a hemolytic uremic syndrome model in the rat. Mar Drugs 2012;10:1582-604. [PMID: 22851928 DOI: 10.3390/md10071582] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
26 Rhee H, Song SH, Lee YJ, Choi HJ, Ahn JH, Seong EY, Lee SB, Kwak IS. Pandemic H1N1 influenza A viral infection complicated by atypical hemolytic uremic syndrome and diffuse alveolar hemorrhage. Clin Exp Nephrol 2011;15:948-52. [PMID: 21826588 DOI: 10.1007/s10157-011-0516-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
27 Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. Transplant Proc. 2012;44:3037-3040. [PMID: 23195022 DOI: 10.1016/j.transproceed.2012.07.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
28 Noone D, Waters A, Pluthero FG, Geary DF, Kirschfink M, Zipfel PF, Licht C. Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol 2014;29:841-51. [DOI: 10.1007/s00467-013-2654-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
29 Krid S, Roumenina LT, Beury D, Charbit M, Boyer O, Frémeaux-Bacchi V, Niaudet P. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant. 2012;12:1938-1944. [PMID: 22494769 DOI: 10.1111/j.1600-6143.2012.04051.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
30 Ranch D, Crowther B, Arar M, Assanasen C. Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation. Pediatr Transplantation 2014;18:E185-9. [DOI: 10.1111/petr.12290] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
31 Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol 2014;36:399-420. [PMID: 24526222 DOI: 10.1007/s00281-014-0416-x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 67] [Article Influence: 11.5] [Reference Citation Analysis]
32 Chen G, Chen S, Chen X. Role of complement and perspectives for intervention in transplantation. Immunobiology. 2013;218:817-827. [PMID: 23182708 DOI: 10.1016/j.imbio.2012.09.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
33 Bitzan M, Lapeyraque A. Postinfectious Hemolytic Uremic Syndrome. In: Geary DF, Schaefer F, editors. Pediatric Kidney Disease. Berlin: Springer Berlin Heidelberg; 2016. pp. 653-731. [DOI: 10.1007/978-3-662-52972-0_26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
34 Knöbl P. Treatment of thrombotic microangiopathy with a focus on new treatment options. Hamostaseologie 2018;33:149-59. [DOI: 10.5482/hamo-13-01-0004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
35 Thurman JM. Therapeutic regulation of complement in patients with renal disease - where is the promise? Clin Nephrol 2012;77:413-23. [PMID: 22551888 DOI: 10.5414/cn107220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
36 Nguyen C, Shapiro R. New immunosuppressive agents in pediatric transplantation. Clinics (Sao Paulo) 2014;69 Suppl 1:8-16. [PMID: 24860853 DOI: 10.6061/clinics/2014(sup01)03] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
37 Dorresteijn EM, van de Kar NC, Cransberg K. Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count. Pediatr Nephrol 2012;27:1193-5. [PMID: 22399074 DOI: 10.1007/s00467-012-2130-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
38 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2015;35:421-47. [PMID: 26456110 DOI: 10.1016/j.nefro.2015.07.005] [Cited by in Crossref: 88] [Cited by in F6Publishing: 63] [Article Influence: 12.6] [Reference Citation Analysis]
39 Yenerel MN. Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management. Turk J Haematol 2014;31:216-25. [PMID: 25319590 DOI: 10.4274/tjh.2013.0374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
40 Breen KA, Seed P, Parmar K, Moore GW, Stuart-smith SE, Hunt BJ. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb Haemost 2017;107:423-9. [DOI: 10.1160/th11-08-0554] [Cited by in Crossref: 63] [Cited by in F6Publishing: 29] [Article Influence: 12.6] [Reference Citation Analysis]
41 Kaplan BS, Ruebner RL, Spinale JM, Copelovitch L. Current treatment of atypical hemolytic uremic syndrome. Intractable Rare Dis Res. 2014;3:34-45. [PMID: 25343125 DOI: 10.5582/irdr.2014.01001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
42 Hoenecke J, Hartmann H, Melk A. Arterial hypertension in children with hemolytic uremic syndrome after kidney transplantation. Pediatr Transplant 2015;19:504-9. [PMID: 26073101 DOI: 10.1111/petr.12533] [Reference Citation Analysis]
43 Pickering M, Cook HT. Complement and glomerular disease: new insights: . Current Opinion in Nephrology and Hypertension 2011;20:271-7. [DOI: 10.1097/mnh.0b013e328345848b] [Cited by in Crossref: 61] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
44 Kaplan BS, Ruebner RL, Copelovitch L. Eculizumab treatment of atypical hemolytic uremic syndrome. Expert Opinion on Orphan Drugs 2012. [DOI: 10.1080/21678707.2013.750579] [Reference Citation Analysis]
45 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document. Nefrología (English Edition) 2015;35:421-47. [DOI: 10.1016/j.nefroe.2015.11.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
46 Palma LM, Langman CB. Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med 2016;7:39-72. [PMID: 27110144 DOI: 10.2147/JBM.S36249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
47 Sullivan M, Rybicki LA, Winter A, Hoffmann MM, Reiermann S, Linke H, Arbeiter K, Patzer L, Budde K, Hoppe B, Zeier M, Lhotta K, Bock A, Wiech T, Gaspert A, Fehr T, Woznowski M, Berisha G, Malinoc A, Goek ON, Eng C, Neumann HP. Age-related penetrance of hereditary atypical hemolytic uremic syndrome. Ann Hum Genet 2011;75:639-47. [PMID: 21906045 DOI: 10.1111/j.1469-1809.2011.00671.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
48 Fremeaux-Bacchi V. Treatment of atypical uraemic syndrome in the era of eculizumab. Clin Kidney J 2012;5:4-6. [PMID: 26069738 DOI: 10.1093/ckj/sfr177] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
49 Bacchetta J, Cochat P. Primary disease recurrence—effects on paediatric renal transplantation outcomes. Nat Rev Nephrol 2015;11:371-84. [PMID: 25917555 DOI: 10.1038/nrneph.2015.54] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
50 Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60. [PMID: 21902819 DOI: 10.1186/1750-1172-6-60] [Cited by in Crossref: 375] [Cited by in F6Publishing: 304] [Article Influence: 34.1] [Reference Citation Analysis]
51 Barnett ANR, Asgari E, Chowdhury P, Sacks SH, Dorling A, Mamode N. The use of eculizumab in renal transplantation. Clin Transplant 2013;27:E216-29. [DOI: 10.1111/ctr.12102] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
52 Rodriguez E, Rallapalli PM, Osborne AJ, Perkins SJ. New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3. Biosci Rep 2014;34:e00146. [PMID: 25188723 DOI: 10.1042/BSR20140117] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 5.9] [Reference Citation Analysis]
53 Montero RM, Sacks SH, Smith RA. Complement-here, there and everywhere, but what about the transplanted organ? Semin Immunol 2016;28:250-9. [PMID: 27179705 DOI: 10.1016/j.smim.2016.04.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
54 Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13:663-675. [PMID: 23356914 DOI: 10.1111/ajt.12077] [Cited by in Crossref: 153] [Cited by in F6Publishing: 139] [Article Influence: 17.0] [Reference Citation Analysis]
55 van Hoeve K, Vandermeulen C, Van Ranst M, Levtchenko E, van den Heuvel L, Mekahli D. Occurrence of atypical HUS associated with influenza B. Eur J Pediatr 2017;176:449-54. [PMID: 28110418 DOI: 10.1007/s00431-017-2856-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
56 Barbour T, Johnson S, Cohney S, Hughes P. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant. 2012;27:2673-2685. [PMID: 22802583 DOI: 10.1093/ndt/gfs279] [Cited by in Crossref: 121] [Cited by in F6Publishing: 93] [Article Influence: 12.1] [Reference Citation Analysis]
57 Raina R, Grewal MK, Radhakrishnan Y, Tatineni V, DeCoy M, Burke LL, Bagga A. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis 2019;12:183-204. [PMID: 31564951 DOI: 10.2147/IJNRD.S215370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
58 Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 2017;30:347-62. [PMID: 27848226 DOI: 10.1007/s40620-016-0357-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
59 Hardinger KL, Brennan DC. Novel immunosuppressive agents in kidney transplantation. World J Transplant 2013; 3(4): 68-77 [PMID: 24392311 DOI: 10.5500/wjt.v3.i4.68] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
60 Bitzan M, Zieg J. Influenza-associated thrombotic microangiopathies. Pediatr Nephrol 2018;33:2009-25. [PMID: 28884355 DOI: 10.1007/s00467-017-3783-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
61 Zwang NA, Ho B, Kanwar YS, Lewis B, Cusick M, Friedewald JJ, Gallon L. A case of atypical hemolytic uremic syndrome in a second renal transplant. J Nephrol 2018;31:165-72. [PMID: 28224376 DOI: 10.1007/s40620-016-0373-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
62 Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol. 2013;24:475-486. [PMID: 23431077 DOI: 10.1681/asn.2012090884] [Cited by in Crossref: 231] [Cited by in F6Publishing: 110] [Article Influence: 25.7] [Reference Citation Analysis]
63 Zuber J, Le Quintrec M, Morris H, Frémeaux-Bacchi V, Loirat C, Legendre C. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev (Orlando). 2013;27:117-125. [PMID: 23937869 DOI: 10.1016/j.trre.2013.07.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 6.2] [Reference Citation Analysis]
64 Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33:508-530. [PMID: 24161037 DOI: 10.1016/j.semnephrol.2013.08.003] [Cited by in Crossref: 204] [Cited by in F6Publishing: 156] [Article Influence: 25.5] [Reference Citation Analysis]
65 Kalluri HV, Hardinger KL. Current state of renal transplant immunosuppression: Present and future. World J Transplant 2012; 2(4): 51-68 [PMID: 24175197 DOI: 10.5500/wjt.v2.i4.51] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
66 Joseph C, Gattineni J. Complement disorders and hemolytic uremic syndrome. Curr Opin Pediatr 2013;25:209-15. [PMID: 23399570 DOI: 10.1097/MOP.0b013e32835df48a] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
67 Gilbert RD, Fowler DJ, Angus E, Hardy SA, Stanley L, Goodship TH. Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B. Pediatr Nephrol 2013;28:1315-8. [DOI: 10.1007/s00467-013-2492-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
68 Hodgkins KS, Bobrowski AE, Lane JC, Langman CB. Clinical grand rounds: atypical hemolytic uremic syndrome. Am J Nephrol 2012;35:394-400. [PMID: 22517061 DOI: 10.1159/000337954] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
69 Wong EK, Goodship TH, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2013;56:199-212. [PMID: 23810412 DOI: 10.1016/j.molimm.2013.05.224] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]
70 Forbes TA, Bradbury MG, Goodship TH, McKiernan PJ, Milford DV. Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: a tertiary case series. Pediatr Transplant 2013;17:E93-9. [PMID: 23461281 DOI: 10.1111/petr.12066] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
71 Sacks SH, Zhou W. The role of complement in the early immune response to transplantation. Nat Rev Immunol 2012;12:431-42. [PMID: 22627861 DOI: 10.1038/nri3225] [Cited by in Crossref: 140] [Cited by in F6Publishing: 126] [Article Influence: 14.0] [Reference Citation Analysis]